



# Market Announcement

3 May 2019

---

## Actinogen Medical Limited (ASX: ACW) – Trading Halt

### Description

The securities of Actinogen Medical Limited ('ACW') will be placed in trading halt at the request of ACW, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Tuesday, 7 May 2019 or when the announcement is released to the market.

### Issued by

**Penelope Reid**

Adviser, Listings Compliance (Perth)



3 May 2019

Ms Anjuli Sinniah  
ASX Operations  
Level 40 Central Park  
152-158 St George's Terrace  
PERTH WA 6000

*Via Email*

Dear Anjuli

## Trading Halt Request

In accordance with ASX Listing Rule 17.1, the Company hereby requests that its securities be placed into an immediate trading halt pending an announcement regarding the disclosure of results from the Phase II XanADu Alzheimer's disease trial.

The Company requests that trading in its securities be halted until after the expected announcement is made or until the market opens on Tuesday, 7 May 2019, whichever is the earlier.

The Company is not aware of any reason why this trading halt request should not be granted.

Yours sincerely

A handwritten signature in black ink, appearing to read "Peter Webse", is written over a light grey rectangular background.

**Peter Webse**  
Company Secretary

**Actinogen Medical**  
Dr. Bill Ketelbey  
CEO & Managing Director  
P: +61 2 8964 7401  
E: bill.ketelbey@actinogen.com.au

@BillKetelbey **About Actinogen Medical**

**Investor and Media Enquiries**  
Arthur Chan  
WE Buchan  
M: +61 2 9237 2805  
E: arthurc@we-buchan.com

## **About Actinogen Medical**

Actinogen Medical (ASX: ACW) is an ASX-listed biotechnology company focused on innovative approaches to treating cognitive decline that occurs in chronic neurological and metabolic diseases. Actinogen Medical is developing its lead compound Xanamem, as a promising new therapy for Alzheimer's disease, a condition with multibillion-dollar market potential and material human impact. In the US alone, the cost of managing Alzheimer's disease is estimated to be US\$250bn and is projected to increase to US\$2tn by 2050, outstripping the treatment costs of all other diseases. Alzheimer's disease is now the leading cause of death in the UK and second only to ischaemic heart disease in Australia. In addition, Actinogen is currently planning an expanded clinical development program for Xanamem in cognitive impairment in mood disorders and schizophrenia. In the US alone, the collective economic costs of mood disorders and schizophrenia are estimated to exceed \$550bn, with the burden increasing every year. The cognitive dysfunction associated with these conditions is significantly debilitating for affected patients, with a substantial unmet medical need for novel, improved treatments.

## **About Xanamem™**

Xanamem's novel mechanism of action sets it apart from other Alzheimer's treatments. It works by blocking the excess production of cortisol - the stress hormone – through the inhibition of the 11 $\beta$ -HSD1 enzyme in the brain. There is a strong association between chronic stress and excess cortisol that leads to changes in the brain affecting memory. The 11 $\beta$ -HSD1 enzyme is highly concentrated in the hippocampus and frontal cortex, the areas of the brain associated with cognitive impairment in neurological diseases, including Alzheimer's disease, mood disorders and schizophrenia.

## **About XanADu**

XanADu is a Phase II double-blind, 12-week, randomised, placebo-controlled study to assess the safety, tolerability and efficacy of Xanamem in subjects with mild dementia due to Alzheimer's disease. XanADu has fully enrolled 186 patients from 25 research sites across Australia, the UK and the USA. Results are expected in Q2 2019. The trial is registered on [www.clinicaltrials.gov](http://www.clinicaltrials.gov) with the identifier: NCT02727699, where more details on the trial can be found, including the study design, patient eligibility criteria and the locations of the study sites.

## **About XanaHES**

XanaHES is a Phase I, randomised, single blinded, central reader blinded, placebo-controlled, dose escalation study to assess the safety and tolerability of Xanamem™ 20mg & 30mg once daily in healthy elderly volunteers. Changes in cognitive performance from baseline to end-of-treatment will be measured as an exploratory efficacy outcome.

**Actinogen Medical encourages all current investors to go paperless by registering their details with the designated registry service provider, Link Market Services.**